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plantation. We performed a retrospective analysis of 70 patients;
20 prior to the institution of Kepivance(palifermin), and 50 pa-
tients after. The preparative regimens include Melphalan, Busulfan
& Etoposide, Cytoxan, BCNU, Etoposide, and Busulfan & Cy-
toxan.
The average length of stay for non-Kepivance patients was 32.3
days compared to 28 days in patients who received the drug. The
severity of both oral and GI mucositis appeared to be less. 85% of
non-Kepivance patients experienced diarrhea or rectal irritation,
versus 52% with Kepivance. Neutropenic fever was noted in 95%
of patients that did not receive the drug and 76% of the patients
that did. There was a trend torward earlier engraftment in the
Kepivance group.
Kepivance seems to have had a positive effect on our patients.
This updated study suggests an improvement in mucositis symp-
toms with the use of Kepivance(palifermin). It appears that mu-
cositis and its treatment contribute to the length of stay and costs
of stem cell transplantation. Qualtiy of life for these patients can be
greatly improved if mucositis is reduced during the course of stem
cell transplantation.
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ROLE OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM
CELL TRANSPLANTATION IN PRIMARY SYSTEMIC AMYLOIDOSIS: A
SYSTEMATIC REVIEW
Behera, M.1, Kharfan-Dabaja, M.A.1, Kumar, A.1, Soares, H.P.1,
Djulbegovic, B.1 1H. Lee Mofﬁtt Cancer Center and Research Institute at
the University of South Florida, Tampa, FL.
Background: Primary systemic amyloidosis (AL) is a rare plasma
cell clonal disorder(8/million) characterized by extracellular depos-
its of material composed mainly of fragments of light chain immu-
noglobulin throughout a body. Standard chemotherapy (e.g. mel-
phalan and prednisone) is associated with poor outcomes (typical
median survival is between 12-18 months with less than 5% sur-
viving 10 years). Autologous stem cell transplant (ASCT) has been
increasingly advocated for the treatment of AL. However, it is
uncertain whether ASCT is better than standard chemotherapy.
To address this uncertainty, we undertook a systematic review/
meta-analysis to evaluate the efﬁcacy of high-dose chemotherapy
and autologous stem-cell transplant (HSCT) versus conventional
chemotherapy in patients with AL.
Methods: We searched for all published studies in Medline and
Cochrane library databases. In addition, we hand searched for
references. Studies were included if they were comparison trials of
HSCT versus conventional chemotherapy, regardless of the trial
design (e.g. randomized controlled trials [RCTs] or prospective
studies with historical control). The studies were eligible if patients
had biopsy proven AL with at least one major organ involved .Data
were extracted on beneﬁts as well as harms (overall survival, event-
free survival, response, treatment related mortality, treatment-
related morbidity).
Results: Out of 34 identiﬁed studies only 4 met the inclusion
criteria for the current systematic review, two of which were RCTs
and two were prospective non-randomized trials that included histor-
ical control. The ages of patients were in the range of 18-69 years.
When we pooled all the data, we found that overall survival was
similar for ASCT and conventional therapy arms [hazard ratio (HR)
of 1.10 (95% CI 0.88, 1.36, p0.4); no signiﬁcant heterogeneity was
found; p 0.6]. Analysis of data according to design (randomized vs.
non-randomized trials) resulted in similar results [HR1.10 (95% CI
0.88, 1.37) and HR0.98 (95% CI 0.29, 3.35), respectively]. The
complete hematologic response was also similar between the 2 arms
[OR 1.38 (95% CI 0.67, 2.85; p0.4].
Conclusion: The results from the meta-analysis indicate that
there is no statistically signiﬁcant difference between the treatment
effects from high-dose chemotherapy with ASCT and conven-
tional chemotherapy. Hence, the efﬁcacy of ASCT in improving
overall survival and complete hematologic response remains to be
proven.
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DOSE DENSE DREIFACH* MELPHALAN100 FOR MULTIPLE MYELOMA
Berz, D.1, McCormack, E.2, Winer, E.2, Karwan, P.2, Colvin, G.2,
Rathore, R.2, Larry, L.2, Elfenbein, G.2, Quesenberry, P.2 1Brown
University, Providence, RI; 2Roger Williams Medical Center, Provi-
dence, RI.
Background: Tandem high dose melphalan therapy with autolo-
gous peripheral stem cell support has emerged as standard of care for
patients without prohibitive comorbidities. Mucositis and gastrointes-
tinal side effects are the most common extrahematologic side effects.
Two previously published studies presented a triple transplant with a
conditioning regimen melphalan 100mg/m2 (MEL100) with periph-
eral stem cell support every two to ﬁve months schedule for patients
with prohibitive comorbidities for high dose tandem transplantation.
We are presenting a novel approach that investigates the triple mel-
phalan100/m2 approach on a dose dense, every three weeks schedule
in a patient population without signiﬁcant comorbidities.
Patients andmethods:Thirteen standard or high risk patients with
stageIII multiple myeloma were prospectively treated. This popula-
tion contained eight patients with IgG clonality, 3 IgA, 1 nonsecretory
and one light chain isotype. The induction regimens of the thirteen
patients were heterogenous and included 5 VAD, 3 DCIE, 2 Thal/
Dex, 2 CIE and 1 pulse decadron. Patients underwent peripheral
blood leukopheresis, and these cells were divided into three equal sets
and frozen. The patients were scheduled to receive Melphalan at
100mg/m2 on day -1, 20, and 41 and then the autologous infusions
occurred at day 0, 21, and 42.
Results: All patients were able to receive all three cycles of the
MEL100 regimen. Seven patients (54%) received the treatments on
the every three week schedule; three treatments (23%) during the
second cycle and six treatments (46%) of the third cycle had to be
delayed a median of 6 and 4 days respectively. Three patients were
managed completely in the outpatient setting, and the average total
hospital stay for the three transplants was 18 days.Median progression
free survival was 854 days (range 73 – 1571) and the overall survival of
this cohort has yet to be reached. No patient had worse than grade II
mucositis, and no serious adverse events were recorded.
Conclusions:Our regimen of three consecutive autologous periph-
eral stem cell transplants with a reduced dose of melphalan at
100mg/m2 given every three weeks is very well tolerated. The pro-
gression free survival and overall survival are similar and can be
compared favorably with the standard tandem myeloma regimens.
Our data is intriguing and further studies with larger numbers need to
be performed to conﬁrm these results. *German for triple.
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OUTCOMES ASSOCIATED WITH AGE IN PATIENTS WITH MALIGNANT
LYMPHOMA RECEIVING AUTOLOGOUS STEM CELL TRANSPLANT
Beveridge, C.A.1, Ershler, W.B.2, Orloff, G.J.1, Sheridan, M.J.3,
Shelton, M.V.1 1Fairfax Northern Virginia Hematology-Oncology, PC,
Fairfax, VA; 2Institute for Advanced Studies in Aging, Washington,
DC; 3Inova Fairfax Hospital, Falls Church, VA.
Background and Rationale
Older age is frequently considered a contraindication to high
dose therapy. We evaluated 32 auto-transplant patients with Ma-
lignant Lymphoma (ML) to determine whether outcomes for those
60 years of age differed from those 60 years of age.
Material and Methods
A retrospective assessment was undertaken of ML patients who
were transplanted at Inova Fairfax Hospital from 2004-2006. All
patients had Karnofsky performance scores of 80% and all were
apheresed using a high volume technique and ideal body weight for
calculations with either G-CSF (G) or GGM-CSF, with a goal of
5106/kg CD34 cells. Patients were treated with growth factor sup-
port using GM-CSF beginning day 4 through ANC recovery of
1000. Blood product replacement was standardized to transfuse for
hemoglobin greater than 8gm/dl or platelet counts of10,000/mm3.
Viability was performed using ﬂow cytometry and propidium iodide.
Continuous variables were analyzed as means and 95% conﬁdence
intervals, but p-values were produced using a Wilcoxon Rank Sum
Test for non-normally distributed data. Categorical variables were
analyzed using a Fisher’s Exact Test.
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Discussion
In ML patients with comparable pretransplant performance sta-
tus, there were no statistical differences in complications, engraft-
ment, cell count yield, cell viability, days of apheresis, platelet
transfusions, or mobilization regimen between older and younger
patients receiving autografts. However, younger patients appeared
to require greater RBC blood product support (p0.05). Our data
suggests that older ML patients with good performance status can
be treated with autologous stem cell treatment strategies compa-
rable to those developed for younger patients.
Results
Variables/Age
Group <60 (N23) >60 p-value
Age (years) 43.9 {38.7, 49.1} 62.9 {60.5, 65.3} <.0001
Days of
Apheresis 2.87 {2.33, 3.41} 2.22 {1.48, 2.97} 0.18
CD 34 yield 5.06 {3.91, 6.20} 6.01 {3.37, 8.65} 0.28
Viability Day 1 83.8 {80.6, 87.0} 87.8 {83.4, 92.1} 0.15
Viability Day 2 84.5 {80.0, 88.2} 83.6 {74.8, 92.4} 0.76
Viability Day 3 82.9 {76.7, 89.0} 80.3 {53.5, 107} 0.57
Days to ANC
Engraftment 12.7 {11.6, 13.8} 12.0 {10.3, 13.7} 0.47
Days to PLT
Engraftment 15.5 {14.0, 17.0} 15.2 {13.6, 16.8} 0.75
Number of
PLT
Transfusions 3.17 {2.14, 4.21} 3.00 {1.41, 4.58} 0.95
Number of
RBC
Transfusions 3.96 {2.74, 5.18} 2.11 {1.35, 3.09} 0.05
Mobilization
Regimen
(%G) 57 67 0.70
Death <100
Days 4.4 0 1.00
Mucositis II-IV
<30 Days 30.4 0 0.15
Sepsis <30
Days 8.7 22.2 0.56
Pneumonia
<30 Days 8.7 0 1.00
Karnofsky
Score 97 99 1.00
93
OUTCOME WITH A THIOTEPA CONTAINING REGIMEN AND AUTOLO-
GOUS HSCT IN PATIENTS WITH NHL
Cumpston, A.D.1, Bulian, D.A.1, Kanate, A.1, Weisenborn, R.1,
Bunner, P.1, Visweshwar, N.I.1, Craig, M.1, Ericson, S.G.1 1West
Virginia University Hospitals, Morgantown, WV.
Introduction: High dose chemotherapy and autologous hemato-
poietic stem cell rescue offers patients with advanced non-hodgkin
lymphoma (NHL) a chance for long-term survival and cure. The role
of thiotepa in this approach is still unknown, and little data with
long-term follow-up has been published. The best chemotherapy
regimen prior to stem cell infusion for patients with NHL remains
unknown.
Methods/Outcome: Twenty-nine patients with advanced NHL
were treated with high dose VP-16, cyclophosphamide, and thio-
tepa followed by autologous HSC rescue from 1993-2006. Median
age was 53 (range 27-69), and all patients except 2 were beyond
CR1. Overall survival and disease-free survival were 76% and 66%
respectively at a median follow-up of 44 months. Five patients
relapsed, with a median time to relapse of 150 days after transplant
(range 82-300 days). Treatment related mortality was 10% (3/29);
all 3 died from infectious complications before day 50. One patient
developed treatment-related myelodysplasia.
Conclusion: An aggressive preparative regimen for autologous
HSCT containing thiotepa offers patients a signiﬁcant chance for
long-term disease-free survival. However, caution is recommended
due to early infectious complications.
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IMMUNE MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD PRO-
GENITOR CELLS: IL-2 WITH GM-CSF AND G-CSF RESULTS IN EFFEC-
TIVE MOBILIZATION WITHOUT DELAY IN ENGRAFTMENT
Hill, J.M.1, Wu, J.-Y.1, Webber, S.1, Sharlin, O.1, Ernstoff, M.S.1,
Szczepiorkowski, Z.M.1, Meehan, K.P.1 1Dartmouth Hitchcock Medical
Center, Lebanon, NH.
We initiated an immune mobilization trial in an attempt to mobilize
cytotoxic effector cells, along with CD34 hematopoietic progenitor
cells. A Prospective Phase I trial was initiated using dose escalation of
IL-2, in combination with GM-CSF and G-CSF. IL-2 began on Day
0 and continued as a daily SQ injection for 11 days. On Day 7,
GM-CSF (7.5 mcg/kg/d) and G-CSF (5 mcg/kg/d) were initiated for
5 days (Days 7-11). On Day 11, leukapheresis was started if the
peripheral blood CD34 cell count was 5 cells/mcl. The endpoint
of collection was 3 106 CD34 cells/kg. After collection, patients
received melphalan (200 mg/m2) followed by infusion of cryopre-
served stem cells. Post-transplant GM-CSF began on Day 5 and
terminated once the ANC reached 5000 cells/mcl. To date, 10 pa-
tients have been treated (myeloma, n 9; NHL, n 1) and 9 patients
are evaluable. Dose escalation of IL-2 continues since the MTD has
not been reached. The ﬁrst two dose levels of IL-2 have been well
tolerated: Dose Level 1 (6 105 IU/m2/d; n 6 pts); and Dose Level
2 (1  106 IU/m2/d; n  3 pts). One patient has completed Dose
Level 3 (1.5  105 IU/m2/d) without difﬁculty. One patient (NHL)
was removed from the study due to progressive disease. The remain-
ing 9 patients completed the regimen. Toxicities have been mild and
have included Grade 2 fever (n1) on Dose Level 2. All patients were
successfully mobilized. The median number of CD34 cells/kg and
MNC/kg collected were 3.4  106 (range 2.8 – 4.4  106/kg) and
9.5  108 (range 0.4 – 1.7  109), respectively. Two large volume
leukaphereses were required (median; range 1 – 3). Following trans-
plant, the ANC recovered on Day 13 (median; range: 10 – 14 d) and
platelets recovered on Day 12 (median; range 0 – 13 d). These
preliminary results demonstrate that immune mobilization and col-
lection of an adequate number of hematopoietic progenitor cells is
feasible without suppression of hematopoiesis. Toxicities are minimal
but the MTD of IL-2 has not yet been reached. Post-transplant
engraftment is not delayed. As patient accrual continues, we are
currently evaluating the qualitative and quantitative components of
the collected cells, including Th1 vs. Th2 cells and the types of
dendritic cells mobilized, while evaluating lymphocyte recovery fol-
lowing transplant.
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AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF A SYSTEM-
ATIC REVIEW
Kharfan-Dabaja, M.A.1, Kumar, A.1, Behera, M.1, Field, T.1,
Ayala, E.1, Perez, L.1, Fernandez, H.1, Anasetti, C.1, Djulbegovic, B.1
1H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL.
Background: Despite improvements in responses, CLL remains
incurable with conventional chemotherapy (CC). About 1/3 of pa-
tients are  60 yrs, and are offered experimental therapies including
high-dose chemotherapy (HDT) and auto-HCT. The objective of
this study is to present the totality of the evidence by conducting a
systematic review to assess the efﬁcacy of auto-HCT in the treatment
of CLL. Methods: A systematic search of the literature was per-
formed using MEDLINE databases (1966- Sep 12, 2006) and hand-
search of references. Included studies were prospective-randomized,
non-randomized or single-arm trials. Data were extracted on primary
outcomes (response rate (RR), overall survival (OS), progression-free
survival (PFS) etc.). Results: Our search identiﬁed altogether 82
publications. Only 8 met our pre-determined inclusion criteria (ta-
ble1). In this cohort of 8 trials, 2 trials were funded by public/
government sources, 2 by private foundations, 1 was funded jointly by
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